Roche sees Lucentis sales increase and announces data from Phase III HARBOR trial
Roche (SIX:ROG; OTCQX:RHHBY) has reported that 3Q11 US sales of Lucentis (ranibizumab) grew by 17% to CHF359M/US$392M. The increase in sales occurs against the backdrop… Read More »Roche sees Lucentis sales increase and announces data from Phase III HARBOR trial